Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation
Author:
Bowen Emily E., Hurcombe Jennifer A., Barrington Fern, Keir Lindsay S., Farmer Louise K., Wherlock Matthew D., Ortiz-Sandoval Carolina G., Bruno Valentina, Bohorquez-Hernandez Arlette, Diatlov Daniel, Rostam-Shirazi Niyousha, Wells Sara, Stewart Michelle, Teboul Lydia, Lay Abigail C., Butler Matthew J., Pope Robert J.P., Larkai Eva M.S., Morgan B. Paul, Moppett John, Satchell Simon C., Welsh Gavin I., Walker Patrick D., Licht Christoph, Saleem Moin A., Coward Richard J.M.ORCID
Reference41 articles.
1. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy;Keir;Pediatr. Nephrol.,2011 2. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression;Garg;JAMA,2003 3. The Syndromes of Thrombotic Microangiopathy: A Critical Appraisal on Complement Dysregulation;Timmermans;J. Clin. Med.,2021 4. Syndromes of thrombotic microangiopathy;George;N. Engl. J. Med.,2014 5. Shiga toxin pathogenesis: kidney complications and renal failure;Obrig;Curr. Top. Microbiol. Immunol.,2012
|
|